暫無數據
代碼股票名稱
最新價漲跌額漲跌幅成交量成交額今開昨收最高最低總市值流通市值總股本流通股本5日漲跌幅10日漲跌幅20日漲跌幅60日漲跌幅120日漲跌幅250日漲跌幅年初至今漲跌幅股息率TTM換手率市盈率TTM市盈率(靜)振幅所屬行業
美股市場個股詳情
AUPH Aurinia Pharmaceuticals
- 4.910
- +0.040+0.82%
收盤價 04/26 16:00 (美東)
- 4.900
- -0.010-0.20%
盤後 19:43 (美東)
7.10億總市值-9092市盈率TTM
5.010最高價4.860最低價98.55萬股成交量4.890今開4.870昨收486.02萬成交額0.75%換手率虧損市盈率(靜)1.45億總股本12.43052周最高1.88市淨率6.47億流通值4.71052周最低--股息TTM1.32億流通股33.972歷史最高--股息率TTM3.08%振幅1.000歷史最低4.931平均價1股每手
全部分時
- 5日
- 日K
- 周K
- 月K
- 季K
- 年K
資金分布
單位: --
資金流向
實時日周月
暫無數據
新聞
Aurinia Pharmicals將在投資者大會上發表演講
快訊 | 更新：2024 年 Bloom Burton & Co. 上的 Aurinia 新演示詳情醫療保健投資者會議
快訊 | Aurinia Pharmicals將於2024年5月2日發佈第一季度財務和運營業績
Aurinia 將參加 2024 年 Bloom Burton & Co.醫療保健投資者會議
Aurinia Pharmicals Inc.（納斯達克股票代碼：AUPH）（Aurinia或該公司）今天宣佈，它將參加2024年的Bloom Burton & Co.醫療保健投資者會議在大多倫多會議中心舉行
Aurinia Pharmicals Inc.（納斯達克股票代碼：AUPH）何時會實現盈虧平衡？
我們什麼時候能指望奧里尼亞製藥公司（納斯達克股票代碼：AUPH）獲利？
我們認爲現在是分析 Aurinia Pharmicals Inc. 的好時機。”s（納斯達克股票代碼：AUPH）的業務看來該公司可能正處於取得重大成就的風口浪尖。Aurinia 製藥
評論
The company's missed forecasts and lack of positive strategic review results may dampen investor sentiment. However, cost savings from discontinuing early-stage drugs and reducing staff, along with share buybacks, could offset some negativity.
Aurinia Drops After Q4 Miss; Strategic Review FailsRecent insider selling activity and lack of trades in the last quarter at Aurinia Pharmaceuticals may concern investors. However, modest insider ownership could suggest alignment between management and smaller shareholders.
Shareholders may not be comfortable amid potentially dimmer future expectations for the company, possibly causing the lower P/S ratio. A shift in the company's fortunes would be required to justify an increase in the P/S.
High confidence in Aurinia Pharmaceuticals with anticipated average yearly growth rate of 71%. A slower rate will delay profitability. Company's debt-free status lowers investment risk.
If the company can sustain its revenue growth, the share price may further increase. The company's performance appears to have improved recently, as the one-year total shareholder return is better than the five-year total shareholder return.
閱讀更多
分析
目標價預測
暫無數據
熱議
美股
綜合熱度
股票代碼
最新價
漲跌幅